BrunoBockornyMD

Gastrointestinal Cancer, Sarcoma

Physician

Dr. Bockorny is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Bruno Bockorny is an oncologist in Boston, MA and is affiliated with Beth Israel Deaconess Medical Center. He received his medical degree from Federal University of Rio de Janeiro School of Medical Sience and has been in practice 13 years. He specializes in gastrointestinal cancer and sarcoma. He has more than 30 publications and over 500 citings.

AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer Start of enrollment: 2024 Apr 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact

PubMed

64 citations
PDX-derived organoids model in vivo drug response and secrete biomarkers.
Ling Huang, Bruno Bockorny, Indranil Paul, Dipikaa Akshinthala, Pierre-Oliver Frappart
JCI Insight. 2020-11-05
6 citations
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
41 citations
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Joseph E. Grossman, Lakshmi Muthuswamy, Ling Huang, Dipikaa Akshinthala, Sofia Perea
Clinical Cancer Research. 2021-11-17

Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023
Novel Strategies Show Winning Potential in Ovarian CancerMarch 28th, 2023
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian CancerMarch 27th, 2023
Join now to see all